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Summary
Background:  To  evaluate  the  feasibility  of  photodynamic  therapy  (NP-PDT)  in  the  palliative
management  of  recurrent/persistent  nasopharyngeal  cancer  (NFC).
Methods: Six  patients  with  persistent/recurrent  NPC  underwent  PDT  with  palliative  intent.  NP-
PDT  was  delivered  by  three  different  methods  depending  on  the  localization,  size  and  depth  of
the  lesion:  type  I  NP-PDT:  transnasal  direct  illumination  of  postero-superior  recurrence;  type
II  NP-PDT:  transnasal  direct  illumination  of  the  whole  nasopharynx;  type  III  NP-PDT:  transoral
direct  or  interstitial  illumination  of  lateral  recurrence.  In  this  case,  the  ENT-magnetic  navigation
system  (MNS)  was  extremely  useful  in  identifying  the  tumor  and  its  distance  from  the  ICA.
Results:  Both  patients  treated  with  NP-PDT  type  I  are  free  from  disease  at  38  and  71  months
after treatment;  both  patients  treated  with  NP-PDT  type  II  experienced  further  local  and  loco-
regional  recurrence  of  disease  within  16  months;  one  died  of  the  disease  while  the  second
underwent  a  second  palliative  treatment,  NP-PDT  type  I,  and  is  currently  living  with  the  disease;
of  the  two  patients  who  underwent  NP-PDT  type  III,  one  died  as  a  result  of  regional  and  systemic
recurrence  without  local  recurrence  while  the  second  experienced  a  superﬁcial  recurrence.  He
underwent  a  second  NP-PDT  type  III  treatment  and  is  currently  free  from  disease  at  21  months.
Conclusions:  NP-PDT  is  a  non-invasive  and  simple  treatment  modality  that  may  have  an  impor-
tant  role  in  the  treatment  of  selected  cases  of  persistent/recurrent  NPC  in  its  early  stage,  not
suitable  for  a  conventional  therapeutic  protocol.  Coupling  NP-PDT  with  the  ENT-MNS  can  be  an
effective  strategy  to  obtain  more  precise  light  delivery  within  the  tumor,  particularly  in  lateral
and  parapharyngeal  localization.
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asopharyngeal  cancer  (NPC),  a  tumor  of  epithelial  origin,
epresents 90%  of  neoplasms  that  develop  in  the  nasopha-
ynx (NP).  It  occurs  sporadically  in  Western  countries,  but
s endemic  in  certain  parts  of  South-East  Asia  (southern
hina, the  Indonesian  archipelago)  [1].  The  worldwide  inci-
ence of  NPC  exceeds  80,000  new  cases/year  with  19,616
ew cases  each  year  in  southern  China  [2].  Epidemiological
ata are  scarce  and  imprecise.  The  incidence  rate,  how-
ver, shows  important  geographical  variations  and  depends
n many  risk  factors  [Epstein—Barr  virus,  genetic  and  envi-
onmental factors,  alimentary  habits  (smoked  and  salted
ood)] [3,4].
The gold  standard  for  primary  NPC  treatment  is  radio-
herapy, combined  with  chemotherapy  in  advanced  stages.
espite the  good  responsiveness  of  NPC,  the  long-term  sur-
ival (10  years)  of  the  disease  ranges  between  67%  and  71%
or T1-2/N0-1  and  between  29%  and  54%  for  locally  advanced
tages (T3-4  and  N2-3).  These  results  are  justiﬁed  by  the
igh local  recurrence  rate  (63.8%)  in  stages  III—IV  and  the
igh rate  of  distant  metastases  (approximately  50%)  in  the
1-2/N2-3 category  [4—6].
Several  options  are  available  for  the  treatment  of  local
ecurrent/persistent NPC  —  surgery  (open  or  endoscopic
pproach), external  re-irradiation,  or  brachytherapy  [7—9]
lone or  in  combination  with  external  re-irradiation  [10]
r stereotactic  radiosurgery  [11].  All  of  these  options
ave advantages  and  disadvantages,  poor  survival  out-
omes and  severe  side  effects.  Only  nasopharyngeal
ndoscopic  resection  seems  to  have  made  a signif-
cant contribution  to  the  reduction  of  complications
12].
Photodynamic therapy  (PDT)  can  represent  a  valid  alter-
ative in  the  treatment  of  selected  recurrent  NPC  in  its
arly stage,  with  either  curative  or  palliative  intent  [13—15].
n the  present  study,  we  report  our  experiences  in  pallia-
ive management  with  PDT  for  six  locally  recurrent  NPC,
ocalized in  different  nasopharyngeal  sites  and  treated  using
hree  different  protocols.
In  two  cases,  PDT  has  been  carried  out  with  the  aid  of
he ENT-magnetic  navigation  system  (MNS)  to  obtain  maxi-
um precision  in  the  delivery  of  light  and  we  are  the  ﬁrst
o describe  the  ergonomics  of  this  technique.
The  aim  of  the  study  was  to  deﬁne  the  precise  indications
or this  type  of  therapy  depending  on  the  tumor  site,  to
escribe the  different  ways  of  delivering  light  to  the  tumor
ith great  precision,  and  to  report  our  preliminary  results
n terms  of  complications  and  local  control.
aterials and methods
etween  January  2005  and  December  2010,  six  patients  (ﬁve
ales and  one  female)  affected  by  persistent/recurrent  NPC
nderwent PDT  with  palliative  intent  at  the  ENT  Depart-
ent of  Martini  Hospital  in  Turin.  All  patients  had  previously
eceived external  beam  radiotherapy  on  the  primary  site  and
eck, with  or  without  concurrent  chemotherapy.  A  bilateral
eck dissection  was  performed  on  one  patient  60  days  after
he end  of  chemo-radiotherapy  due  to  cervical  persistence
f disease.
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All  locally  recurrent  NPC  were  fully  investigated  to
onﬁrm the  stage  in  the  primary  site  and  the  status
f the  cervical  lymph  nodes.  The  investigations  included
osterior rhinoscopy  with  biopsy,  maxillofacial  and  neck
RI or  CT-scan,  chest  X-ray,  and  total  body  PET-scan.
ll patients  showed  histologically  proven  local  persis-
ence/recurrence of  NPC  classiﬁed  as  rT1  and  rT2a  according
o the  2007  (7th  Edition)  Union  Internationale  Contre
e Cancer  (UICC)/American  Joint  Committee  on  Cancer
AJCC) TNM  system.  As  a  rule,  only  cases  without  neck
ecurrence and  distant  metastasis  were  considered  for
DT.
In three  cases,  it  was  not  possible  to  offer  alternative
reatments because  of  poor  general  condition  or  severe
omorbidities while  in  the  remaining  three  cases,  patients
id not  accept  the  conventional  (surgery  or  re-irradiation)
reatments proposed.
The  treatment  protocol  was  approved  by  the  Ethics  Com-
ittee of  Martini  Hospital  of  Turin  and  the  patients  signed  a
peciﬁc informed  consent  before  the  procedure.
hotodynamic therapy
ll  patients  were  subjected  to  slow  intravenous  injection
≥6 min)  of  Temoporﬁn  (Foscan®) at  a  dose  of  0.15  mg/kg
ith activation  of  the  drug  after  96  h.  In  the  time  interval
etween administration  of  the  drug  and  its  activation  (DLI),
he patients  were  maintained  at  home  in  a  darkened  room
curtains drawn,  light  bulbs  no  brighter  than  60  W)  (not  more
han 200  lux).
In all  cases,  the  illumination  was  performed  in  the  oper-
ting room  under  general  anesthesia,  for  optimal  patient
omfort and  to  obtain  a  better  exposure  of  the  lesion.  For
ctivation, a  laser  light  of  wavelength  652  nm  was  used,
t a  dose  of  20  J/cm2 and  an  intensity  of  100  mW/cm2
or  200  s.  Photosensitizer  activation  was  achieved  with
 diode  laser  system  (Biolitech),  delivering  light  using
ber optics  with  a  microlens  for  superﬁcial  illumina-
ion or  through  a  cylindrical/bare  ﬁber  optic  inserted
ithin the  mass  for  interstitial  illumination  of  the  tumor.
ormal laser  safety  precautions  were  required  for  the
atient.
In the  postoperative  period,  the  patients  received
herapy with  antibiotics,  opiates  and  non-steroidal  anti-
nﬂammatory drugs.
Exposure to  light  was  gradually  increased  to  about  200
ux per  day  over  a  period  of  approximately  2  weeks,  giving
n average  hospitalization  of  8.3  days  (min.  6  days,  max.  15
ays).
After discharge,  the  patients  received  regular  follow-
p scheduled  at  15,  30,  and  60  days  after  the  procedure
nd then  every  2  months,  during  which  the  degree  of
esponse to  treatment  and  any  complications  or  sequelae
ere evaluated.  A  control  biopsy  and  a  maxillofacial/neck
RI-CT-scan were  performed,  not  earlier  than  12  weeks
fter PDT.  A  complete  disappearance  of  the  lesion  with
egative biopsy  was  deﬁned  as  complete  response  (CR),  a
eduction of  more  50%  of  the  volume  of  the  lesion  with  pos-
tive biopsy  was  deﬁned  as  partial  response  (PR),  and  a  lack
f response  or  progression  of  the  disease  as  null  response
NR).
Precision  photodynamic  therapy  65
Fig.  1  (a)  Small  recurrence  at  the  nasopharyngeal  postero-superior  wall  (rT1).  (b)  The  MRI  shows  the  superﬁcial  nasopharyngeal
recurrence (red  arrow)  and  a  second  primary  tumor  at  the  external  auditory  canal  (yellow  arrow).
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applicator (Type  III  NP-PDT)  (Fig.  8a—c).  Five  out  six  patients
(83.3%) showed  a  CR  to  treatment  and  only  in  one  case
was there  a  PR.  The  follow-up  period  ranged  from  24  to  71Fig.  2  Type  I  NP-PDT.  (a)  Illumination  planning.  (b)  The  gree
left side.
Type I  NP-PDT: transnasal direct illumination
of  postero-superior recurrence
Two  patients  had  a  small-sized  recurrence  at  the  nasopha-
ryngeal postero-superior  wall  (rT1).  The  ﬁrst  case  was  a
persistence after  chemo-radiotherapy  interruption  due  to
the onset  of  a  demyelinating  neuropathy.  The  second  case
was a  recurrent  NPC,  12  years  after  the  previous  chemo-
radiotherapy, associated  with  a  second  primary  tumor
localized to  the  external  auditory  canal  and  extending
to the  parotid  gland  (Fig.  1a  and  b).  The  patient  under-
went an  initial  surgical  procedure  (subtotal  petrosectomy,
total parotidectomy,  neck  dissection)  and  then  declined
any further  treatment  other  than  radiotherapy  on  the  neck
and temporal  region;  in  particular,  the  patient  refused  an
endoscopic resection  of  recurrent  NPC.  In  these  cases,  we
proceeded to  a  superﬁcial  treatment  by  transnasal  direct
illumination through  both  nasal  cavities.  A  laser  ﬁber  optic
was used  with  a  0◦,  4  mm  telescope  (Karl-Storz,  Tuttlingen,
Germany). One  or  multiple  spots  were  planned  to  illuminate
the visible  lesion,  depending  on  the  diameter  and  morphol-
ogy of  the  tumor  (Fig.  2a  and  b).  As  in  ordinary  surgery,  a
safety margin  of  0.5—1  cm,  enclosing  normal  tissue  around
the tumor,  was  included  in  the  treatment  ﬁeld  (Figs.  3—7).Results
No  side  effects  were  observed  in  patients  during  drug  injec-
tion for  PDT.  PDT  was  well  tolerated  and  in  the  postoperative
F
w
riding  light  during  the  treatment  shows  a  safety  margin  on  the
eriod,  all  patients  complained  of  pain,  especially  during
wallowing. In  one  patient,  a  nasogastric  tube  (NGT)  was
ecessary temporarily,  due  to  intense  dysphagia.  In  one
atient, we  observed  acute  skin  toxicity  from  early  expo-
ure to  light,  with  second-degree  burns  to  the  forearm  which
ere treated  with  medical  dressing.
Patients  undergoing  superﬁcial  or  blended  precision  PDT
Type I  or  Type  II  NP-PDT)  complained  of  nasopharyngeal
urns of  lower  grade  than  patients  treated  with  Van  Veen’sig.  3  Type  II  NP-PDT:  transnasal  direct  illumination  of  the
hole nasopharynx,  using  Van  Veen’s  device.  Single  contempo-
ary illumination.
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Fig.  4  (a)  Recurrence  at  the  lateral  nasopharyngeal  wall  (rT1)  in  Rosenmüller’s  fossa.  (b)  The  MRI  shows  a  recurrence  involving
Rosenmüller’s  fossa  toward  the  parapharyngeal  space  (red  arrow).  (For  interpretation  of  the  references  to  color  in  this  ﬁgure  legend,
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ahe  reader  is  referred  to  the  web  version  of  the  article.)
onths;  at  the  time  of  last  follow-up,  three  patients  (50%)
ere free  from  disease,  one  (16.6%)  was  alive  with  disease
nd two  (33.3%)  had  died  from  disease.  No  postoperative
djuvant treatment  was  delivered  (Fig.  9).
Both  patients  treated  with  NP-PDT  type  I are  free  from
isease at  follow-up  of  71  and  38  months,  respectively.
ne patient  developed  a  regional  recurrence  28  months
fter PDT  and  underwent  modiﬁed  radical  neck  dissection
Table 1).
s
r
c
ig.  5  Type  III  NP-PDT:  transoral  direct  illumination  of  lateral  naso
llows  a  double  control,  optical  and  radiological.iscussion
ifferent  strategies  are  available  for  the  salvage  treatment
f early-stage  local  failures  of  NPC:  surgery  ±  radiotherapy,
rachytherapy alone  [7—9]  or  in  combination  with  exter-
al re-irradiation  [10]  and  ﬁnally,  stereotactic  radio-
urgery [16].  The  standard  treatment  for  advanced
ecurrent/persistent  NPC  is  sequential  or  concomitant
hemo-re-irradiation  [11].
pharyngeal  wall.  The  use  of  ENT-MNS  and  transnasal  endoscopy
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aFig.  6  Type  III  NP-PDT:  transoral  interstitial  illumination  of
endoscopy allows  a  double  control,  optical  and  radiological.
The  unsatisfactory  surgical  exposure  and  the  high  fre-
quency of  destructive  surgical  complications  using  open
approaches have  prompted  the  development  of  a  minimally
invasive surgical  method  to  overcome  the  limitations  of  cur-
rent surgical  methodologies.  Endoscopic  procedures  have
opened new  and  innovative  surgical  possibilities  [12].
In  a  series  of  17  consecutive  patients  with  primary
or recurrent  NPC  treated  with  pure  endoscopic  resection,
Castelnuovo et  al.  [12]  have  classiﬁed  three  different  types
Fig.  7  Type  III  NP-PDT:  transoral  interstitial  illumination  of
lateral nasopharyngeal  wall.  The  previously  marked  bare  ﬁber
optic is  inserted  inside  the  curved  suction  cannula  coupled  to
the ENT-MNS.  (a)  Starting  position  for  pull-back  illumination;  (b)
ﬁnal position.
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oral  nasopharyngeal  wall.  The  use  of  ENT-MNS  and  transnasal
f  nasopharyngeal  endoscopic  resection  (NER),  graded  from
 to  3  on  the  basis  of  the  extent  of  resection,  with  71%
isease-free survival  and  a  median  follow-up  of  41  months.
In  this  scenario,  PDT  could  represent  a  straightforward
nd effective  alternative  treatment  option.  In  the  litera-
ure, several  articles  have  shown  that  PDT  is  effective  in
estroying NPC,  with  good  local  control  of  tumor  growth
nd complete  responses  in  the  majority  of  small  recurrent
r persistent  disease  (rT1—T2)  and  long-term  palliation  in
dvanced stage  (rT3—T4)  disease  [13,15].
By  analyzing  the  cases  in  this  series,  it  can  be  said
hat three  out  of  six  cases  could  have  been  submitted  to
 surgical  or  radio-chemotherapy  salvage  treatment  with
n excellent  chance  of  success,  but  this  was  not  possible
ecause the  patients  would  only  accept  minimally  invasive
alliative treatment.  In  the  remaining  three  cases,  because
f the  severe  comorbidity,  it  was  not  possible  to  suggest
ny conventional  salvage  treatment.  Despite  the  limitations
elated to  a  palliative  therapy  outcome,  NP-PDT  has  been
erformed using  the  same  principles  underlying  the  endo-
copic resections,  such  as  preoperative  imaging  evaluation
nd the  maximum  accuracy  in  directing  the  light,  obtained
y endoscopic  control  coupled  with  the  ENT  MNS.  This  is  ﬁrst
ime that  the  use  of  this  technology  coupled  with  PDT  for
he treatment  of  recurrent  NPC  has  been  described.
PDT  is  essentially  a  cancer  treatment  working  on  the  sur-
ace of  the  tumor;  its  limitation  is  related  to  the  fact  that
ight needed  to  activate  most  photosensitizers  cannot  pass
hrough more  than  about  1  cm  of  tissue.  In  order  to  treat
eeper lesions,  it  is  necessary  to  deliver  the  activating  light
nside the  lesion  by  diffusion  from  cylindrical  or  bare  ﬁber
ptics, thus  obtaining  interstitial  PDT  (IPDT).  Positioning  the
68  G.  Succo  et  al.
Table  1  Clinical  characteristics  of  patients.
N  Gender  Age  AJCC  TNM
stage at
diagnosis
Primary
treatment
AJCC TNM
stage  at
recurrence
Time  of
recurrence
(mo)
Type  of
NP-PDT
Response
to  PDT
Site  and
time  of
further
recurrence
(mo)
Further
treatment
Follow-
up
1  F  56  T2N0M0  CHT-RT  rT1N0M0  6  I  CR  Regional  mRND  NED
(71  mo)
2 M  54  T2N0M0  CHT-RT  rT1N0M0  144  I  CR  Regional  —  NED
(38  mo)
3 M  65  T1N0M0  RT rT1N0M0  12  II  PR  Loco-
regional
NP-PDT
type I
LWD
(25  mo)
4 M  59  T2N0M0  CHT-RT+
neck
dissection
rT2N0M0  27  II  CR  Loco-
regional
[12]
— DWD
(20  mo)
5 M  37  T2N2bM0  CHT-RT+
neck
dissection
rT1N0M0  48  III  CR  Local  [12]  NP-PDT
type  III
NED
(21  mo)
6 M  67  T2N0M0  CHT-RT  rT2N0M0  36  III  CR  Regional
+  systemic
[16]
—  DWD
(28  mo)
CHT, chemotherapy; RT, radiotherapy; CR, complete response; PR, partial response; NP-PDT, nasopharyngeal photodynamic therapy;
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nmRND, modiﬁed radical neck dissection; NED, no evidence of dise
bers  about  1.5  cm  away  from  each  other  will  deliver  the
ctivating light  within  the  tumor,  providing  sufﬁcient  over-
ap and  avoiding  less  illuminated  areas.
In  view  of  these  physical  characteristics  of  light  diffusibil-
ty, the  treatment  of  recurrent  NPC  is  substantially  different
epending on  the  site.  Recurrence  localized  to  the  posterior
all/roof of  the  nasopharynx  is  broadly  superﬁcial,  in  most
ases not  thicker  than  1  cm,  with  underlying  bone  (bony  ﬂoor
f the  sphenoid  sinus,  ventral  portion  of  the  clivus,  atlas)
nd absence  of  important  anatomical  structures.  The  most
rgonomic  option  for  light  delivery  is  the  direct  transnasal
oute (NP-PDT  type  I),  with  the  ﬁber  optics  carried  on  a  0◦
 mm  telescope,  normally  used  in  endoscopic  sinus  surgery.
he light  thus  reaches  the  treatment  area  perpendicularly,
ith maximum  tissue  penetration  and  easily  reaching  the
nderlying bone.  By  reducing  the  endoscopic  white  light,
he bright  green  light  of  the  diode  laser  is  dominant,  which
llows the  PDT  activating  light  to  be  targeted  with  great  pre-
ision, with  intensity  equal  to  652  nm.  If  the  tumor  affects
 large  portion  of  the  posterior  wall,  multiple  spots  can  be
sed, passing  through  both  nasal  fossae.
When  the  recurrence  affects  the  lateral  nasopharyngeal
all, we  are  dealing  with  a  tumor  extending  deeper  into
osenmüller’s fossa,  involving  peritubaric  and  parapharyn-
eal tissue.  It  is  therefore  absolutely  necessary  to  accurately
dentify important  structures  such  as  the  ICA  and  know  the
istance separating  the  vessel  from  the  tumor.  Previous
xperience has  shown  that  PDT  is  not  indicated  when  the
umor directly  affects  the  adventitia  of  the  arterial  vessel,
lacing it  at  risk  of  rupture  [18,19].  It  is  clear,  therefore,
hat superﬁcial  PDT  can  only  treat  the  vegetating  portion
f the  tumor,  whereas  it  is  impossible  to  treat  the  tumor
n Rosenmüller’s  fossa  and  peritubaric  tissues  without  using
PDT.
t
t
NDWD, died with disease; LWD, living with disease.
To  overcome  these  technical  aspects,  coupling  NP-PDT
ith the  ENT-MNS  seemed  interesting  using  transoral  access
or treatment  and  transnasal  access  for  endoscopic  control
NP-PDT type  II).  With  this  solution,  the  distance  between
he lighting  ﬁber  optic  tip  carried  on  a  navigated  curved
uction cannula  and  the  area  to  be  illuminated  is  larger,
hus obtaining  a  spot  of  adequate  size,  a  more  perpendicu-
ar orientation  of  the  light  and  very  good  control  thanks  to
ndoscopy and  probe  direction  assessment.
The  same  strategy  was  adopted  in  IPDT  for  treatment
f the  deep  part  of  the  tumor;  the  tip  of  the  navi-
ated curved  suction  cannula  was  positioned  in  contact
ith the  tumor  at  the  level  of  Rosenmüller’s  fossa  and
he bare  ﬁber  optic  for  pull-back  lighting  was  introduced
nto the  tumor  reaching  the  distal  end.  The  ENT-MNS  was
xtremely useful  to  accurately  identify  the  tumor  and  its
istance from  the  ICA,  providing  the  surgeon  with  accu-
ate and  continuous  intraoperative  monitoring  of  treatment
ccuracy.
The third  adopted  strategy  for  treatment  of  bulky  recurr-
nces, involving  more  NP  subsites,  was  NP-PDT  with  Van
een’s device  [17]  (NP-PDT  type  III),  similar  to  that  used
or brachytherapy.  This  device  allows  an  extensive  superﬁ-
ial treatment  of  the  NP  and,  compared  to  the  two  other
ypes of  treatment,  results  in  lower  selectivity,  the  inability
o treat  the  deeper  part  of  the  tumor  and  a  lengthy  post-
perative period,  as  a  result  of  lighting  of  the  whole  NP.  In
ur opinion,  such  treatment  can  be  advantageously  replaced
y a  more  precise  PDT,  arising  from  the  routine  use  of  the
avigator.It can  therefore  be  said  that  precision  PDT,  coupled  with
he above  described  systems,  is  potentially  able  to  achieve
he same  effectiveness  as  NER  only  on  the  soft  tissues  of  the
P and  adjacent  sites  but  is  obviously  limited  because  it  is
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Fig.  8  Early  endoscopic  control  after  NP-PDT,  showing  different  grades  of  nasopharyngeal  burns.  (a)  Type  I  NP-PDT;  (b)  Type  III
NP-PDT;  (c)  Type  II  NP-PDT.
P-PD
t
d
vFig.  9  Endoscopic  follow-up  control  after  NP-PDT.  (a)  Type  I  N
NED  at  24  mo.
not  able  to  resect  the  underlying  bone  tissue;  this  theoreti-
cally puts  NP-PDT  at  a  lower  level  of  effectiveness  compared
to NER,  which  should  therefore  be  considered  to  be  the
standard conventional  treatment  at  the  present  time.  On
the  other  hand,  NP-PDT  is  a  simpler  method,  rapid  and  eas-
ily repeatable,  especially  using  the  ENT-MNS.  In  our  study,
NP-PDT offered  to  patients  as  palliative  therapy  to  treat
slow tumor  growth  has  proved  to  be  a  very  effective  local
Fig.  10  Possible  reﬁnement  of  endoscopic  control  in  Type  III
NP-PDT: the  navigated  curved  suction  cannula  and  ﬁber  optic
are tethered  to  a  70◦ angled  telescope  that  allows  coaxial  vision
with the  laser  light.
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sT:  no  evidence  of  disease  (NED)  at  71  mo;  (b)  Type  III  NP-PDT:
reatment,  without  severe  side  effects,  resulting  in  good
isease-free survival  (50%),  and  comparable  with  other  sal-
age  treatments.
Another important  advantage  is  its  repeatability,  as
hown in  this  series.  PDT  does  not  have  cumulative  effects.
n the  case  of  a  partial  response,  the  same  area  could  be
lluminated again.
Further  reﬁnements  of  the  technique  are  possible.  The
ossibility to  tether  a 70◦ angled  telescope  to  the  curved
robe coupled  to  the  MNS  is  under  study  in  order  to  obtain
oaxial optical  control  of  the  area  to  be  illuminated  by  tran-
oral access  (Fig.  10)  as  well  as  trying  to  illuminate  the
ateral nasopharyngeal  wall  by  positioning  the  70◦ telescope
ethered to  a  curved  suction  cannula  in  the  contralateral
hoana.
onclusions
recision  NP-PDT  may  have  a  signiﬁcant  role  in  the  treat-
ent of  selected  persistent/recurrent  NPC  (rT1—T2a)  not
uitable for  further  conventional  treatment.  The  preliminary
urvival outcomes  appear  encouraging,  and  are  compara-
le with  other  salvage  treatments.  The  main  advantages
f PDT  are  the  lower  morbidity,  the  repeatability,  the
mproved preservation  of  surrounding  tissues  and  negligible
ide effects.
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Although  preliminary  results  are  encouraging  and  consid-
ring the  good  precision  that  comes  with  coupling  NP-PDT
nd the  ENT-MNS,  more  clinical  experience  in  terms  of  the
nowledge of  proper  light  dosimetry,  as  is  performed  in
adiotherapy, is  still  needed  to  fully  address  the  role  of
hotodynamic therapy  as  a  salvage  treatment  option  for
ersistent/recurrent nasopharyngeal  carcinoma.
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